Future clinical studies can assess the combination of multiple biomarkers, such as cardiac markers (troponins and BNP/NT-proBNP) and other circulating NET markers (neutrophil elastase) [35], to better understand the relationship between tumor progression and cardiotoxicity. The gene discussed is NPPB; the disease is neoplasm.